Back to Search
Start Over
Early death incidence and prediction in stage IV large cell neuroendocrine carcinoma of the lung.
- Source :
-
Medicine [Medicine (Baltimore)] 2024 Sep 13; Vol. 103 (37), pp. e39294. - Publication Year :
- 2024
-
Abstract
- Nearly half of lung large cell neuroendocrine carcinoma (LCNEC) patients are diagnosed at an advanced stage and face a high early death risk. Our objective was to develop models for assessing early death risk in stage IV LCNEC patients. We used surveillance, epidemiology, and end results (SEER) databases to gather data on patients with stage IV LCNEC to construct models and conduct internal validation. Additionally, we collected a dataset from the Second Affiliated Hospital of Nanchang University for external validation. We used the Pearson correlation coefficient and variance inflation factor to identify collinearity among variables. Logistic regression analysis and least absolute shrinkage and selection operator analysis were employed to identify important independent prognostic factors. Prediction nomograms and network-based probability calculators were developed. The accuracy of the nomograms was evaluated using receiver operating characteristic curves. The goodness of fit of the nomograms was evaluated using the Hosmer-Lemeshow test and calibration curves. The clinical value of the models was assessed through decision curve analysis. We enrolled 816 patients from the surveillance, epidemiology, and end results database and randomly assigned them to a training group and a validation group at a 7:3 ratio. In the training group, we identified 9 factors closely associated with early death and included them in the prediction nomograms. The overall early death model achieved an area under the curve of 0.850 for the training group and 0.780 for the validation group. Regarding the cancer-specific early death model, the area under the curve was 0.853 for the training group and 0.769 for the validation group. The calibration curve and Hosmer-Lemeshow test both demonstrated a high level of consistency for the constructed nomograms. Additionally, decision curve analysis further confirmed the substantial clinical utility of the nomograms. We developed a reliable nomogram to predict the early mortality risk in stage IV LCNEC patients that can be a helpful tool for health care professionals to identify high-risk patients and create personalized treatment plans.<br />Competing Interests: The authors have no conflicts of interest to disclose.<br /> (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Subjects :
- Humans
Male
Female
Middle Aged
Aged
Incidence
ROC Curve
Prognosis
Carcinoma, Large Cell mortality
Carcinoma, Large Cell pathology
Carcinoma, Large Cell epidemiology
Risk Assessment methods
Carcinoma, Neuroendocrine mortality
Carcinoma, Neuroendocrine pathology
Carcinoma, Neuroendocrine epidemiology
Lung Neoplasms mortality
Lung Neoplasms pathology
Nomograms
SEER Program
Neoplasm Staging
Subjects
Details
- Language :
- English
- ISSN :
- 1536-5964
- Volume :
- 103
- Issue :
- 37
- Database :
- MEDLINE
- Journal :
- Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 39287289
- Full Text :
- https://doi.org/10.1097/MD.0000000000039294